Jakarta, CNBC Indonesia – The race to find the Covid-19 vaccine continues. According to Soumya Swaninathan, chief scientist at the World Health Organization, there are two leading vaccine candidates to return to normal life.
There are at least two companies in the forefront in making vaccines. Namely, a British pharmaceutical company, AstraZeneca in collaboration with the Universities of Oxford and Moderna.
“Of course in terms of how advanced (the vaccine) is, the stage where they are, they are the main candidates. So maybe they (Astra and Moderna) will get fairly early results,” Swaminathan said at a press conference as quoted by Reuters. Monday (6/29/2020).
“We know that the Moderna vaccine will also go into phase three clinical trials, perhaps starting in mid-July, and so that vaccine candidates are not far behind,” Swaminathan said.
“But I think AstraZeneca certainly has a more global scope right now in terms of where they conduct and plan their vaccine trials,” he continued.
Swaminathan also revealed that the WHO was in talks with several Chinese manufacturers, including Sinovac about potential vaccines. He also said that he was studying the vaccine with Indian researchers.
Previously, AstraZeneca, which was listed on the New York Stock Exchange (NYSE) and London Stock Exchange. The company plans to produce 2 billion doses of the new corona virus vaccine that causes Covid-19. This includes 400 million for the US and UK, and 1 billion for people in low and middle income countries.
WHO alone recorded 16 Covid-19 vaccines that have been tested on humans. Phase three clinical trials have a wider number of vaccine trials to the public to determine the effectiveness and efficacy of vaccines.
Even though the vaccine has entered the final phase three clinical trial, there is no guarantee that this vaccine will succeed. Sign in there is a possibility the vaccine failed to become a weapon against corona. The following 16 vaccines are being developed worldwide and have been tested in humans:
- University of Oxford / AstraZeneca, UK, Phase 3
- CanSino Biological Inc./Beijing Institute of Biotechnology, China, Fase 2
- Moderna / NIAID, United States, Phase 2
- Wuhan Institute of Biological Products/Sinopharm, China, Fase 1/2
- Beijing Institute of Biological Products/Sinopharm, China, Fase 1/2
- Sinovac, China, Fase 1/2
- Novavax, United States, Phase 1/2
- BioNTech/Fosun Pharma/Pfizer, Jerman, Fase 1/2
- Institute of Medical Biology, Chinese Academy of Medical Sciences, China, Fase 1
- Inovio Pharmaceuticals, United States, Phase 1
- Genexine Consortium, South Korea, Phase 1
- Gamaleya Research Institute, USA Seritkat, Phase 1
- Clover Biopharmaceuticals Inc./GSK/Dynavax, China, Fase 1
- Anhui Zhifei Longcom Biopharmaceutical/Institute of Microbiology Chinese Academy of Sciences, China, Fase 1
- Imperial College London, England, Phase 1
- Curevac, Germany, Phase 1
